Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine

Calcitonin gene-related peptide (CGRP) is linked to migraine attacks. Researchers tested a CGRP-receptor antagonist, BIBN 4096 BS, for treating migraines. This trial involved 126 patients who received either placebo or varying doses of the drug. A group-sequential adaptive design was used to ensure patient safety. The 2.5-mg dose showed a response rate of 66%. In comparison, the placebo response rate was only 27%. Overall, the BIBN 4096 BS group had a response rate of 60%. The drug showed significant benefits for secondary endpoints, including pain relief. Improvement was seen in symptoms like nausea and sensitivity to light. Effects started within 30 minutes and improved over hours. Adverse events occurred in 25% of patients taking the 2.5-mg dose. Common side effects included paresthesia. Fortunately, there were no serious adverse events reported. BIBN 4096 BS effectively treats acute migraine attacks. Clinical relevance: This research indicates that BIBN 4096 BS may provide effective acute migraine relief.